The Best News for HEXO Stock Investors This Christmas

HEXO has halted dilutive equity raises, as the company targets becoming earnings and cash flow positive.

| More on:
Person Hands Opening Mailbox To Remove Newspaper

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn moresdf

Soon after the marijuana firm implemented a revised share consolidation on December 18, HEXO’s (TSX:HEXO)(NYSE:HEXO) stock price rose 3.9% on Tuesday after the cannabis firm released a more reassuring press release on December 22.

The latest news is that the cannabis grower has allowed its base shelf prospectus to lapse this month. Investors in HEXO stock may welcome the news for two solid and bullish reasons. Firstly, the company has halted shareholder dilution. Secondly, management is confident about suppressed cash burn and future profitability outlook.

HEXO halts shareholder dilution

In December 2018, the company filed a prospectus to raise up to $800 million in new equity financing during a 25-month period between November 2018 and December 2020.

HEXO utilized just under a third of the planned equity raising capacity. The company only raised $254.3 million between January 2019 and August 2020. After a successful turnaround strategy, “the company has determined not to file another short-form base shelf prospectus at this time,” the latest press release pointed out.

The company once flirted with the possibility of bankruptcy at one point. Lenders gave management a deadline by which to raise new equity. The stock price was in free fall, and there was no guarantee that the markets will continue to fund the firm. Fortunately, funding was secured just in time.

Management doesn’t see a need for new and dilutive equity financing anymore. At least not in the near term. The executive team is positive on the firm’s balance sheet and cash flow outlook. As noted earlier, the numbers are coming right at HEXO.

The company is on course to generate positive cash flow

Management noted a growing oversupply of marijuana in the Canadian market earlier than peers in 2019. It decided to halt further investment in operations and expansion projects. The company shut down operations at selected production sites, disposed of some, and laid off several employees, as it sought to downsize operations given obtaining market conditions.

The plan to right-size operations has been a successful turnaround strategy so far.

Revenue continues to grow while operating expenses remain contained. Cash flow from operations has been improving throughout 2020, as the company reported ever-improving adjusted EBITDA numbers sequentially for six consecutive quarters. We have seen free cash flow generation improve sequentially over five quarters now.

HEXO quarterly Revenue and Free Cash Flow May 2018-October 2020
HEXO’s net revenue is growing every quarter, and free cash flow is improving sequentially. Source: Koyfin.

The company has made tremendous progress in positioning its brands in Canada. It signed international supply deals and launched new, successful products while retaining market leadership in Quebec.

Analysts expect HEXO to report its first positive cash flow from operations in the third quarter of fiscal 2021. The first positive adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) reading is also expected for fiscal second-quarter 2021 ending January 31, next year.

“We are also progressing on the path of becoming cash-flow positive from our operations,” said HEXO CFO, Trent MacDonald in the December 22nd press release. “In light of our solid financial position, and most notably our excellent liquidity and cash flow position, we do not see the need to conduct further rounds of financing in the near future,” he concluded.

Investor takeaway

Investors are noticing HEXO’s tangible progress made during the year 2020. The numbers look much better, and the outlook is encouraging. However, its stock price hasn’t responded much — yet.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Brian Paradza has no position in any of the stocks mentioned. The Motley Fool recommends HEXO. 

More on Cannabis Stocks

Cannabis smoke
Cannabis Stocks

Canopy Growth Stock: Is Now a Good Time to Invest?

The road ahead is highly uncertain for Canopy Growth, as the stock is plagued with losses and seemingly unsurmountable industry…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

TLRY Stock: Should You Invest Now?

TLRY is a Canadian cannabis stock which is trading 91% below record highs. Let's see if you should own TLRY…

Read more »

Cannabis grows at a commercial farm.
Cannabis Stocks

Is Tilray Stock a Buy in February 2023?

Despite the volatile cannabis sector, Tilray could be a superb buy for long-term investors.

Read more »

Young woman sat at laptop by a window
Cannabis Stocks

Is SNDL Stock a Buy in February 2023?

SNDL is a beaten-down cannabis stock. While its revenue growth is exceptional, a weak balance sheet has driven stock prices…

Read more »

A cannabis plant grows.
Cannabis Stocks

TLRY Stock: Here’s What’s Coming in 2023

Tilray Inc. (TSX:TLRY) is geared up for big growth this decade and looks like one of the top cannabis stocks…

Read more »

A person holds a small glass jar of marijuana.
Cannabis Stocks

Canopy Growth Stock: Here’s What’s Coming in 2023

Canopy Growth stock has made a lot of new moves in the last few months, but where is the company…

Read more »

A cannabis plant grows.
Cannabis Stocks

Better Cannabis Buy: Canopy Growth Stock or Tilray?

Only two TSX weed stocks can deliver substantial returns in the highly anticipated growth of the global cannabis market.

Read more »

Medicinal research is conducted on cannabis.
Cannabis Stocks

Is Tilray Stock a Buy in January 2023?

Tilray stock has lost 50% of its value in the last 12 months, in line with its peers.

Read more »